| 1 |
Review Detection and management of pre-existing cognitive impairment and associated behavioral symptoms in the Intensive Care Unit. 2008
Lee HB, DeLoatch CJ, Cho S, Rosenberg P, Mears SC, Sieber FE. · Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD 21287-5371, USA. · Crit Care Clin. · Pubmed #18929940 No free full text.
Abstract: Recent increase in both the elderly population and associated incidence of dementia are of critical importance to patient care in ICUs in the United States. Identification of pre-existing cognitive impairment, such as mild cognitive impairment and dementia, could prevent delirium and associated morbidity and mortality in the ICU. Additionally, noncognitive behavioral symptoms, such as depression, psychosis, agitation, and catastrophic reactions, are common in patients with pre-existing cognitive impairment. Detection and management of noncognitive behavioral symptoms associated with MRI and dementia in ICU leads to improved delivery of life-saving critical care.
|
| 2 |
Article Activation of 5-HT4 receptors inhibits secretion of beta-amyloid peptides and increases neuronal survival. 2007
Cho S, Hu Y. · Neuroscience Discovery Research, Wyeth Research, CN 8000, Princeton, NJ 08543, USA. · Exp Neurol. · Pubmed #16978609 No free full text.
Abstract: Activation of 5-HT4 receptors has been shown to improve memory processes in preclinical cognition models, suggesting potential utility of 5-HT4 agonists for the symptomatic treatment of Alzheimer's disease (AD). Recent studies have shown that 5-HT4 agonists also increase the secretion of the non-amyloidogenic soluble amyloid precursor protein-alpha (sAPPalpha). In the present study, we demonstrated that a selective 5-HT4 partial agonist, RS67333, inhibited the generation of beta-amyloid peptide (Abeta) in primary cortical cultures of Tg2576 transgenic mice expressing human APP(K670N/M671L). Furthermore, treatments with RS67333 selectively increased the survival of transgenic neurons in a dose-dependent manner, which was inhibited by 5-HT4 antagonists. These and previous data collectively suggest that the 5-HT4 receptor may be an effective therapeutic target for AD, providing both symptomatic improvements and neuroprotection.
|
|
|